A Randomized, Double-blind, Placebo Controlled, Parallel Group, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06412562 In Psychiatrically Stable Subjects With Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2016
At a glance
- Drugs PF 6412562 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Pfizer
- 18 Nov 2016 Status changed from recruiting to completed.
- 09 Jun 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.
- 09 Jun 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016.